Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07310797

Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion

This randomized controlled trial compares the efficacy and safety of four treatment strategies for ureteral stone expulsion: Mirabegron alone, Tamsulosin alone, a combination of both, and standard conservative care. Participants diagnosed with ureteral stones will be randomly assigned to one of these four groups. The primary objective is to evaluate the stone expulsion rate within 4 weeks. The study also assesses time to expulsion, pain intensity, analgesic use, and potential side effects.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

About this study

This study aims to compare the efficacy of Mirabegron, Tamsulosin, their combination, and standard conservative management in facilitating ureteral stone expulsion, as well as to evaluate their impact on clinical symptoms.

The primary objective is to analyze the differences in the stone expulsion rate within four weeks among four treatment groups:

Group A: Mirabegron 50 mg daily.

Group B: Tamsulosin 0.4 mg daily.

Group C: Combination of Mirabegron 50 mg and Tamsulosin 0.4 mg daily.

Group D: Standard of care (symptomatic control). For acute colic, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as Ketorolac or Diclofenac are the first-line treatment. If patients have allergies or contraindications to NSAIDs, alternative analgesics such as Tramadol or Acetaminophen will be administered.

Secondary objectives include comparing the time to stone expulsion, changes in pain intensity (assessed by Visual Analog Scale), consumption of analgesic medication, and the impact of different treatments on patient fatigue (assessed by the Fatigue Symptom Inventory, FSI).

Additionally, the study will collect and analyze adverse events occurring during the treatment period, such as palpitations, blood pressure changes, and headaches, to evaluate the safety of each intervention. The results are expected to provide comprehensive options for Medical Expulsive Therapy (MET), offering alternative non-invasive strategies for patients intolerant to traditional alpha-blockers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age and Sex: Adult patients aged 18 to 75 years, inclusive of both males and females.
  • Diagnosis: Unilateral ureteral stone confirmed by Computed Tomography (CT), Renal Sonography, or Kidney-Ureter-Bladder (KUB) radiography.
  • Stone Characteristics: Stone size between 4 mm and 10 mm; located in the upper (proximal), middle, or lower (distal) ureter.
  • Symptoms and Renal Function: Presence of renal colic or hematuria, with no severe renal insufficiency (eGFR > 60 mL/min/1.73m²).

Exclusion criteria

  • Urinary tract infection (UTI).
  • Multiple or bilateral ureteral stones.
  • Ureteral stones not visible on KUB radiography (radiolucent stones).
  • Pregnant or lactating women.
  • Severe hydronephrosis.
  • Renal insufficiency (defined as eGFR < 30 mL/min/1.73m² or Serum Creatinine > 2 mg/dL).
  • Uncontrolled hypertension or major cardiovascular disease.
  • Patients who refuse Medical Expulsive Therapy (MET).

Treatment and study plan

Mirabegron

Drug

50 mg tablet orally once daily.

Tamsulosin

Drug

0.4 mg tablet orally once daily.

Primary outcomes

  1. Stone Expulsion Rate

    Time frame: Up to 4 weeks

    The proportion of participants with complete stone expulsion confirmed by KUB or CT scan. Successful expulsion is defined as the absence of stone fragments or the presence of clinically insignificant fragments.

Secondary outcomes

  1. Time to Stone Expulsion

    Time frame: Up to 4 weeks

    The number of days from randomization to the confirmation of complete stone expulsion.

  2. Change in Pain Intensity

    Time frame: Baseline and up to 4 weeks

    Assessed using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst possible pain).

  3. Total Analgesic Consumption

    Time frame: Up to 4 weeks

    The total amount of analgesic medication (e.g., NSAIDs, Tramadol, Acetaminophen) consumed by the participant to control pain.

  4. Change in Fatigue Symptoms

    Time frame: Baseline and up to 4 weeks

    Assessed using the Fatigue Symptom Inventory (FSI) to measure the intensity and interference of fatigue.

  5. Incidence of Adverse Events

    Time frame: Up to 4 weeks

    Number of participants with treatment-related adverse events, such as palpitations, hypotension, dizziness, and headache.

Study contacts

Contact information is provided by the study sponsor or research team.

Shu-Yu Wu, Doctor of Medicine

CONTACT

[email protected]

+886-2-6628-9779 ext. 60146

Sponsors and collaborators

Lead sponsor

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

Other

Registry information

Official study title

A Randomized Controlled Trial Comparing Mirabegron and Tamsulosin for Ureteral Stone Expulsion and Clinical Symptom Improvement

Important dates

Study start
2026
Primary completion
2029
Study completion
2030
First posted
Dec 30, 2025
Registry last updated
Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.